New treatment for lung cancer metastases using a special therapy
Development of IFNA2-LNP01 for tumor lung metastases immunotherapy
This study is testing a new treatment called IFNA2-LNP01 to help cancer patients with lung metastases by using a special delivery system to boost their immune system before surgery, with the hope of shrinking tumors and making surgery safer and more effective.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Chemedimmune, INC. NIH-funded |
| Lab location | 1 site (Martinez, United States) |
| Project ID | NIH-10820250 on NIH RePORTER |
What this research studies
This research focuses on developing a new therapy called IFNA2-LNP01, which is designed to treat lung metastases in cancer patients. The therapy involves using a lipid nanoparticle to deliver a specific type of DNA that activates the immune system to fight cancer cells in the lungs. By administering this treatment before surgery, the goal is to reduce the size or number of lung metastases, making more patients eligible for potentially life-saving surgical procedures. The research aims to improve survival rates for patients with colorectal cancer and other cancers that have spread to the lungs.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with lung metastases from colorectal cancer or other malignancies who are currently not eligible for surgery.
Not a fit: Patients with lung metastases that are not amenable to surgical intervention or those with other advanced-stage cancers may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly increase the number of patients eligible for surgical treatment of lung metastases, potentially improving survival rates.
How similar studies have performed: While the approach of using immune therapies for cancer treatment is gaining traction, this specific application of IFNA2-LNP01 for lung metastases is relatively novel and has not been extensively tested in prior studies.
Where this research is happening
Martinez, United States
- Chemedimmune, INC. — Martinez, United States (Active)
Researchers
- Principal investigator: Redd, Priscilla Simon — Chemedimmune, INC.
- Study coordinator: Redd, Priscilla Simon
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.